Remove Structure Based Drug Design (SBDD) Remove Targeted Protein Degradation Remove Trials
article thumbnail

Molecules of the Month – June 2023

Drug Hunter

danuglipron – An oral GLP-1-RA full agonist in Phase IIb clinical trials for obesity and Phase II trials for type 2 diabetes mellitus, identified through sensitized cell high-throughput screening and optimization, originated from Pfizer. Request a trial to check out substructure search and more features. Not a member?